elliptinium has been researched along with Benign Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abele, R; Brugarolas, A; Cavalli, F; Clarysse, A; de Jager, R; Hansen, HH; Renard, G; Rozencweig, M; Siegenthaler, P | 1 |
| Crespeigne, N; Cumps, E; Dodion, P; Kenis, Y; Kisner, D; Nicaise, C; Piccart, M; Rozencweig, M | 1 |
| Amiel, JL; Droz, JP; Gouyette, A; Huertas, D; Rouesse, J | 1 |
| Amiel, JL; Dat-Xuong, N; Garnier, H; Juret, P; Le Pecq, JB; Paoletti, C; Rouesse, J | 1 |
| Cibas, I; Einzig, AI; Gralla, RJ; Greenberg, E; Kelsen, DP; Lewis, E; Leyland-Jones, BR | 1 |
1 review(s) available for elliptinium and Benign Neoplasms
| Article | Year |
|---|---|
Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
Topics: Alkaloids; Animals; Antineoplastic Agents; Drug Evaluation; Drug Evaluation, Preclinical; Ellipticines; Humans; Mice; Neoplasms; Neoplasms, Experimental; Rats | 1980 |
4 other study(ies) available for elliptinium and Benign Neoplasms
| Article | Year |
|---|---|
Phase II study of 9-hydroxy-2N-methylellipticinium acetate.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Evaluation; Ellipticines; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms | 1984 |
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Drug Administration Schedule; Drug Evaluation; Ellipticines; Female; Humans; Male; Middle Aged; Neoplasms | 1982 |
Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Evaluation; Ellipticines; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Protein Binding | 1982 |
Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
Topics: Adolescent; Adult; Aged; Alkaloids; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Ellipticines; Female; Hemolysis; Humans; Male; Middle Aged; Neoplasms; Uremia | 1985 |